Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study.
Saved in:
| Title: | Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple-negative breast cancer: Results from the triple-negative breast cancer cohort of the phase 2 LEAP-005 Study. |
|---|---|
| Authors: | Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Saada-Bouzid E; Department of Medical Oncology, Cote d'Azur University, Centre Antoine Lacassagne, Nice, France., Longo F; Medical Oncology Department, Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria, Centro de Investigación Biomédica en Red Cáncer, Alcalá University, Madrid, Spain., Yanez E; Oncology-Hematology Unit, University of Frontera, Araucanía, Chile., Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Castanon E; Department of Oncology, Clínica Universidad de Navarra, Madrid, Spain., Desautels DN; Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada., Graham DM; Experimental Cancer Medicine Team, The Christie National Health Service Foundation Trust, Manchester, UK.; University of Manchester, Manchester, UK., Garcia-Corbacho J; Clinical Institute of Hemato-Oncological Diseases, Hospital Clinic, Barcelona, Spain., Lopez J; Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK., Dutcus C; Eisai Inc., Nutley, New Jersey, USA., Okpara CE; Eisai Ltd., Hatfield, UK., Ghori R; Merck & Co., Inc., Rahway, New Jersey, USA., Jin F; Merck & Co., Inc., Rahway, New Jersey, USA., Groisberg R; Merck & Co., Inc., Rahway, New Jersey, USA., Korakis I; Department of Medicine and Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse, France. |
| Source: | Cancer [Cancer] 2024 Oct 01; Vol. 130 (19), pp. 3278-3288. Date of Electronic Publication: 2024 Jun 21. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Multicenter Study |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1097-0142 |
|---|---|
| DOI: | 10.1002/cncr.35387 |
